Novo Nordisk filed a request with the Food and Drug Administration to add semaglutide to its Demonstrable Difficulties for Compounding lists, to prohibit compounding pharmacies from producing semaglutide formulations that would compete with its Ozempic and Wegovy drugs. It argues that the drugs are too complicated to compound safely.
“These drugs are inherently complex to compound safely, and the risks they pose to patient safety far outweigh any benefits. Novo Nordisk’s aim with this nomination is to ensure that patients receive only FDA-approved, safe, and effective semaglutide product,” director of media relations Jamie Bennett told the magazine WIRED.
NCPA
